Literature DB >> 14756433

Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response.

Taro Oshikiri1, Masaki Miyamoto, Toshiaki Shichinohe, Masato Suzuoki, Kei Hiraoka, Yoshihiro Nakakubo, Toshiya Shinohara, Tomoo Itoh, Satoshi Kondo, Hiroyuki Katoh.   

Abstract

BACKGROUND AND OBJECTIVES: Tumor-infiltrating lymphocytes form an important aspect of the host defense against an expanding neoplasm. CD8+ T cells have been identified as a prognostic factor in several cancers. Here, we investigate that the influence of CD8+ T cells on extrahepatic bile duct carcinoma (EBDC) patient survival.
METHODS: CD8+ T cell immunoreactivity in 58 surgically resected EBDC specimens was investigated. The relationship between CD8+ T cell immunoreactivity and clinical and histopathologic features was analyzed.
RESULTS: Thirty-two tumors (55%) possessed intratumoral CD8+ T cells. The degree of intratumoral CD8+ T cell immunoreactivity demonstrated a significant relationship to lower numbers of lymph node metastasis, reduced venous invasion, decreased perineural invasion, and better pTNM staging. Intratumoral CD8- T cells were also associated with increased patient survival. Multivariate analysis indicated that the presence of intratumoral CD8+ T cells was an independent prognostic factors.
CONCLUSIONS: The infiltration of a cancer cell nest by CD8+ T cells is a reliable marker predicting increased survival of patients with EBDC.

Entities:  

Mesh:

Year:  2003        PMID: 14756433     DOI: 10.1002/jso.10321

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  39 in total

1.  Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: its prognostic significance.

Authors:  Tadahiro Nozoe; Yoshihiko Maehara; Keizo Sugimachi
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

2.  A Novel Prognostic Score Combining Preoperative Biliary Drainage and Inflammatory Status for Patients with Periampullary Cancers.

Authors:  Yuki Fujiwara; Koichiro Haruki; Ryoga Hamura; Takashi Horiuchi; Yoshihiro Shirai; Kenei Furukawa; Takeshi Gocho; Hiroaki Shiba; Katsuhiko Yanaga
Journal:  J Gastrointest Surg       Date:  2019-05-06       Impact factor: 3.452

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 4.  Immune reaction and colorectal cancer: friends or foes?

Authors:  Vincenzo Formica; Vittore Cereda; Antonella Nardecchia; Manfredi Tesauro; Mario Roselli
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.

Authors:  Jan Hrudka; Kateřina Lawrie; Petr Waldauf; Vanda Ciprová; Jana Moravcová; Radoslav Matěj
Journal:  Virchows Arch       Date:  2020-05-18       Impact factor: 4.064

6.  Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Takeshi Muto; Hayato Sasaki; Kazuhide Urabe; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

Review 7.  Current Progress in Immunotherapy for the Treatment of Biliary Cancers.

Authors:  James M Pauff; Laura W Goff
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 8.  Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.

Authors:  Alex B Blair; Adrian Murphy
Journal:  Curr Probl Cancer       Date:  2017-10-31       Impact factor: 3.187

Review 9.  Current status of immunotherapy for the treatment of biliary tract cancer.

Authors:  Ryuji Takahashi; Munehiro Yoshitomi; Shigeru Yutani; Takahisa Shirahama; Masanori Noguchi; Akira Yamada; Kyogo Itoh; Tetsuro Sasada
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

10.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.